PIP Search Page

Displaying 41 - 60 of 107

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check	Date Published Sort ascending
MHRA-100555-PIP01-22	vepsitamab	Treatment of gastric cancer and gastro-oesophageal junction cancer Treatment of colorectal carcinoma Treatment of pancreatic cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100565-PIP01-22	MDM2-p53 antagonist	Treatment of liposarcoma		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100493-PIP01-22	BI 765128 - humanized monoclonal antibody of IgG1 subtype targeting NRP1	Diabetic retinopathy		Ophthamology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100632-PIP01-22-M01 (update)	FLUCICLOVINE (18F)	Diagnosis of amino acid metabolism in solid malignant tumours	Axumin Axumin Axumin Axumin Axumin Axumin Axumin Axumin	Diagnostic Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100316-PIP02-22	latozinemab	Treatment of Amyotrophic lateral sclerosis		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100186-PIP01-21	depemokimab	Treatment of chronic rhinosinusitus with nasal polyps (CRSwNP)	Depemokimab	Pneumology - Allergology	W: decision granting a waiver in all age groups for the listed condition(s).	No	25/05/2023
MHRA-100634-PIP01-22	Ceralasertib	Treatment of lung carcinoma (small cell and non-small cell carcinoma)		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	02/02/2023
MHRA-100472-PIP01-22	Tarlatamab	Treatment of small cell lung cancer (SCLC) Treatment of prostate malignant neoplasms.		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	02/02/2023
MHRA-100251-PIP01-21	DUPILUMAB	Chronic pruritus of unknown origin	Dupixent Dupixent Dupixent Dupixent Dupixent	Dermatology	W: decision granting a waiver in all age groups for the listed condition(s).	No	02/02/2023
MHRA-100572-PIP01-22	autologous bone marrow-derived mononuclear cell enriched white blood cells	Treatment of chronic limb-threatening ischemia		Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No	02/02/2023
MHRA-100556-PIP01-22	Anti-C1s Humanized IgG4 Monoclonal Antibody	Treatment of chronic inflammatory demyelinating polyradiculoneuropathy		Neurology Immunology -Rheumatology-Transplantation Haematology-Hemostaseology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100458-PIP01-22	Modakafusp alfa	Treatment of multiple myeloma		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100135-PIP02-22	anti-CD40L humanised monoclonal antibody (SAR441344)	Treatment of progressive Multiple Sclerosis		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100476-PIP01-22	Anti-(alpha-synuclein) human monoclonal antibody	Treatment of Multiple System Atrophy Treatment of Parkinson's Disease		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100481-PIP01-22	TUCATINIB	Treatment of solid tumours	Tukysa	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100404-PIP01-21	insulin icodec SEMAGLUTIDE	Treatment of type 2 diabetes mellitus		Endocrinology-Gynaecology-Fertility-metabolism	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100365-PIP01-21	Batiraxcept	Treatment of Ovarian cancer Treatment of Fallopian tube cancer Treatment of Primary peritoneal cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100395-PIP01-21	TALAZOPARIB TOSYLATE	Treatment of breast malignant neoplasms Treatment of prostate malignant neoplasms	Talzenna Talzenna Talzenna Talzenna Talzenna Talzenna	Psychiatry Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100366-PIP01-21	Cevostamab	Treatment of multiple myeloma		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100383-PIP01-21	TRASTUZUMAB DERUXTECAN	Treatment of lung cancer	Enhertu Enhertu Enhertu	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022

Download XLSX

Search Filters: